Business
Longeveron Announces Multiple Presentations at the 11th Annual International Conference on Frailty & Sarcopenia Research
MIAMI, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing
About this update from Longeveron Inc.
[{"type":"text","content":"MIAMI, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (\"Longeveron\" or \"Company\"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related, and life-threatening conditions, today announced that the Company’s Lomecel-B research program will be featured in two presentations and a roundtable discussion at the 11th Annual International Conference on Frailty & Sarcopenia Research (ICFSR), taking place virtually September 29 - October 2, 2021. The ICFSR conference was created to speed the development of high-quality clinical trials in frail older adults with the goal of accelerating the discovery of treatments, prevention methods for healthy aging and prevention of disabilities and dependency in older adults. Roundtable details as follows: Title: Topline Results from the Phase 2b Study of Lomecel-B in Patients with Aging Frailty Presenter: Dr. Jorge Ruiz, M.D., Geriatrics Research Education and Clinical Center (GRECC), Miami VA Healthcare SystemDate: Wednesday, September 29, 2021Time: 11:30 – 12:10 p.m. ET A live panel with Dr. Ruiz and Longeveron management will follow the presentation. Oral presentation details and schedules are as follows: Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study in Japan to Investigate the Safety and Efficacy of Lomecel-B administration by Longeveron in patients with Aging Frailty: Study Design and Rationale.Abstract ID: OC34Date: Wednesday, September 29, 2021Time: 01:00 AM EST (release of on-demand recording)Title: Study Design and Rationale for HERA: A Phase I/II study evaluating the effects of Intravenous Delivery of Lomecel-B on Vaccine-Specific Antibody Responses in Subjects with Aging Frailty. Abstract ID: OC58Date: Friday, October 1, 2021Time: 01:00 AM EST (release of on-demand recording) Those interested in registering for the conference can find more information at the conference website: https://frailty-sarcopenia.com/. All three presentations will be posted to Longeveron’s website after the conference under “Events & Presentations” in the Investors section of the Company’s website at investors.longeveron.com. About Longeveron Inc. Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product ...